- Home
- ATNI vs XFOR Comparison
ATNI vs XFOR Comparison
Compare ATNI & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATNI | XFOR |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.0M | 323.5M |
| IPO Year | 1991 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATNI | XFOR |
|---|---|---|
| Price | $22.93 | $3.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $28.50 |
| AVG Volume (30 Days) | 41.8K | ★ 403.9K |
| Earning Date | 03-03-2026 | 11-05-2025 |
| Dividend Yield | ★ 4.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $724,308,000.00 | $33,979,000.00 |
| Revenue This Year | $1.77 | $1,266.01 |
| Revenue Next Year | $2.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2925.74 |
| 52 Week Low | $13.76 | $1.35 |
| 52 Week High | $23.76 | $24.43 |
Technical Indicators
Market Signals| Indicator | ATNI | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 54.83 | 45.99 |
| Support Level | $21.44 | $3.57 |
| Resistance Level | $23.68 | $3.89 |
| Average True Range (ATR) | 0.86 | 0.18 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 67.72 | 25.00 |
Price Performance
Historical ComparisonAbout ATNI ATN International Inc.
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.